Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosomes | 6 | 2025 | 135 | 2.710 |
Why?
|
| Chromatin | 11 | 2025 | 602 | 1.920 |
Why?
|
| Chromosome Mapping | 4 | 2017 | 284 | 0.730 |
Why?
|
| Mitosis | 2 | 2025 | 209 | 0.730 |
Why?
|
| Genome | 3 | 2023 | 257 | 0.680 |
Why?
|
| Hodgkin Disease | 2 | 2011 | 55 | 0.670 |
Why?
|
| DNA | 5 | 2024 | 806 | 0.640 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2007 | 13 | 0.620 |
Why?
|
| Nucleic Acid Conformation | 4 | 2024 | 234 | 0.600 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2012 | 474 | 0.580 |
Why?
|
| MicroRNAs | 5 | 2012 | 618 | 0.570 |
Why?
|
| Gene Expression Profiling | 5 | 2009 | 720 | 0.550 |
Why?
|
| Staining and Labeling | 1 | 2017 | 124 | 0.520 |
Why?
|
| Genome, Human | 2 | 2017 | 225 | 0.500 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2011 | 52 | 0.460 |
Why?
|
| Laryngeal Neoplasms | 3 | 2011 | 52 | 0.450 |
Why?
|
| Carcinoma | 3 | 2007 | 116 | 0.390 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2025 | 168 | 0.390 |
Why?
|
| Fas-Associated Death Domain Protein | 2 | 2011 | 11 | 0.390 |
Why?
|
| Formaldehyde | 3 | 2023 | 32 | 0.370 |
Why?
|
| Cell Cycle Proteins | 2 | 2025 | 385 | 0.360 |
Why?
|
| Multiprotein Complexes | 2 | 2025 | 153 | 0.350 |
Why?
|
| Chromosomes, Human | 2 | 2021 | 53 | 0.340 |
Why?
|
| Cross-Linking Reagents | 3 | 2021 | 117 | 0.330 |
Why?
|
| Adenosine Triphosphatases | 2 | 2025 | 253 | 0.330 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2007 | 3 | 0.290 |
Why?
|
| Genomics | 2 | 2023 | 322 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 264 | 0.290 |
Why?
|
| DNA-Binding Proteins | 2 | 2025 | 1151 | 0.250 |
Why?
|
| Cell Line | 3 | 2021 | 1984 | 0.240 |
Why?
|
| Cell Nucleus | 2 | 2023 | 608 | 0.240 |
Why?
|
| Animals | 11 | 2025 | 19680 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 278 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 119 | 0.220 |
Why?
|
| Animal Fins | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cell Line, Tumor | 5 | 2011 | 1368 | 0.210 |
Why?
|
| Prophase | 2 | 2025 | 15 | 0.210 |
Why?
|
| DNA Restriction Enzymes | 1 | 2023 | 35 | 0.200 |
Why?
|
| Interphase | 2 | 2025 | 68 | 0.200 |
Why?
|
| Biological Evolution | 1 | 2023 | 114 | 0.190 |
Why?
|
| Replication Origin | 1 | 2022 | 36 | 0.190 |
Why?
|
| Spermatozoa | 1 | 2023 | 253 | 0.190 |
Why?
|
| Genetic Techniques | 1 | 2021 | 39 | 0.180 |
Why?
|
| Chromosomes, Mammalian | 2 | 2020 | 33 | 0.180 |
Why?
|
| Melanoma | 1 | 2023 | 318 | 0.170 |
Why?
|
| Humans | 20 | 2025 | 59476 | 0.160 |
Why?
|
| Cortactin | 3 | 2011 | 4 | 0.150 |
Why?
|
| Prometaphase | 1 | 2018 | 6 | 0.150 |
Why?
|
| Xenopus laevis | 1 | 2018 | 67 | 0.140 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2017 | 25 | 0.140 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 99 | 0.140 |
Why?
|
| Biotin | 1 | 2017 | 51 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 295 | 0.140 |
Why?
|
| Base Sequence | 2 | 2017 | 1302 | 0.130 |
Why?
|
| Computational Biology | 1 | 2018 | 334 | 0.120 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 214 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 529 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 300 | 0.100 |
Why?
|
| Binding, Competitive | 1 | 2012 | 98 | 0.100 |
Why?
|
| RNA, Antisense | 1 | 2012 | 49 | 0.090 |
Why?
|
| Cyclin D1 | 2 | 2011 | 19 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2017 | 383 | 0.090 |
Why?
|
| Gene Targeting | 1 | 2011 | 78 | 0.090 |
Why?
|
| Cloning, Molecular | 1 | 2012 | 381 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 32 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1554 | 0.080 |
Why?
|
| Cisplatin | 1 | 2010 | 119 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2011 | 645 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 237 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 289 | 0.080 |
Why?
|
| Palatine Tonsil | 1 | 2009 | 9 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2011 | 461 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2010 | 271 | 0.080 |
Why?
|
| Germinal Center | 1 | 2009 | 38 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 47 | 0.080 |
Why?
|
| CCCTC-Binding Factor | 2 | 2020 | 40 | 0.080 |
Why?
|
| RNA Interference | 1 | 2012 | 590 | 0.070 |
Why?
|
| Models, Biological | 1 | 2013 | 1143 | 0.070 |
Why?
|
| Nucleic Acid Probes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Poly A | 1 | 2007 | 27 | 0.070 |
Why?
|
| Embryonic Stem Cells | 2 | 2020 | 151 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 62 | 0.070 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 27 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2023 | 133 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2007 | 90 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 87 | 0.070 |
Why?
|
| Gene Duplication | 1 | 2006 | 31 | 0.070 |
Why?
|
| Artifacts | 1 | 2007 | 125 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 152 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 148 | 0.060 |
Why?
|
| Chromatids | 1 | 2025 | 15 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 884 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 628 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2005 | 112 | 0.060 |
Why?
|
| DNA Damage | 1 | 2006 | 279 | 0.060 |
Why?
|
| Time Factors | 2 | 2012 | 3619 | 0.060 |
Why?
|
| Histone Code | 1 | 2023 | 26 | 0.050 |
Why?
|
| Uveal Neoplasms | 1 | 2023 | 51 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 651 | 0.050 |
Why?
|
| Melanocytes | 1 | 2023 | 77 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2023 | 241 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2020 | 2095 | 0.050 |
Why?
|
| S Phase | 1 | 2022 | 76 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2023 | 229 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 254 | 0.050 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2021 | 35 | 0.050 |
Why?
|
| Polymers | 1 | 2024 | 316 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 461 | 0.040 |
Why?
|
| DNA Replication | 1 | 2022 | 230 | 0.040 |
Why?
|
| Zebrafish | 1 | 2023 | 326 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2020 | 51 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 450 | 0.040 |
Why?
|
| Male | 5 | 2023 | 27794 | 0.040 |
Why?
|
| Mammals | 1 | 2020 | 209 | 0.040 |
Why?
|
| Nucleosomes | 1 | 2020 | 185 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 377 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 815 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 10308 | 0.030 |
Why?
|
| Indoleacetic Acids | 1 | 2017 | 31 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 331 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 841 | 0.030 |
Why?
|
| Fixatives | 1 | 2012 | 17 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2012 | 21 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 35 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 42 | 0.020 |
Why?
|
| Glottis | 1 | 2011 | 13 | 0.020 |
Why?
|
| Gene Library | 1 | 2012 | 98 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 192 | 0.020 |
Why?
|
| Chromones | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2010 | 19 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 394 | 0.020 |
Why?
|
| Morpholines | 1 | 2010 | 86 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 587 | 0.020 |
Why?
|
| Tonsillitis | 1 | 2009 | 2 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 188 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2009 | 3 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 179 | 0.020 |
Why?
|
| Carbonic Anhydrases | 1 | 2009 | 8 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 107 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 56 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1598 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 96 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1029 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1057 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1237 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 1033 | 0.010 |
Why?
|
| Aged | 2 | 2011 | 13423 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 248 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 365 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 411 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1796 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 5125 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1469 | 0.010 |
Why?
|
| Child | 1 | 2009 | 4205 | 0.010 |
Why?
|
| Female | 2 | 2011 | 30779 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 5854 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 2901 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 15704 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 16339 | 0.010 |
Why?
|